Phase 3 study

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor AstraZeneca
Registry number NCT07784270
Started 20 August 2026 Today 16 October 2026 Estimated completion 8 August 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site Botany NSW Recruiting
Research Site Camberwell VIC Recruiting
Research Site Charlestown NSW Not yet recruiting
Research Site Helensvale QLD Not yet recruiting
Research Site Maroubra NSW Recruiting
Research Site Waitara NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 1500

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Males \& females (inclusive of all gender identities) age ≥18 years

* BMI ≥27 kg/m2

* Diagnosed with T2DM ≥90 days prior to Screening

* HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)

* Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation

* History of at least one self-reported unsuccessful attempt to lose body weight in lifetime

Exclusion Criteria:

* Obesity primarily caused by other endocrine disorders

* Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening

* Significant hepatobiliary disease and/or any of the following results at Screening:

* ALT ≥ 3.0 X ULN

* AST ≥ 3.0 X ULN

* TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome)

* Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation

* Use of insulin therapy for T2DM within 3 months prior to screening

Dates on the record

Started 20 August 2026
Estimated completion 8 August 2028
Registry last updated 22 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 22 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.